botulinum toxin type A (HG-102) / Hugel - LARVOL DELTA

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines (clinicaltrials.gov) - P3 | N=272 | Recruiting | Sponsor: Hugel | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head

A Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Compare the Efficacy and Safety of HG102 Versus Botox® in Subjects With Moderate to Severe Glabellar Lines (clinicaltrials.gov) - P3 | N=274 | Not yet recruiting | Sponsor: Hugel

Head-to-Head • New P3 trial

HG-BOT102GL-PI-01: To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines. (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Hugel | Active, not recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Dec 2021

Trial completion • Trial completion date